Madrigal insider plans Rule 144 sale of 429 shares

Madrigal Pharmaceuticals insider files to sell 429 shares of common stock under Rule 144.

Accepted by SEC EDGAR 01/20/2026 - 04:39 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Madrigal Pharmaceuticals insider files to sell 429 shares of common stock under Rule 144. The shares have an aggregate market value of $215,220.72 and are to be sold through Morgan Stanley Smith Barney LLC on or after an approximate sale date of 01/20/2026 on the NASDAQ exchange. The securities were acquired from the issuer on 01/16/2026 as restricted stock units, in the same amount of 429 shares. Madrigal Pharmaceuticals had 22,711,420 shares outstanding of common stock at the time referenced in the notice.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for MDGL disclose?

The Form 144 for MDGL discloses a proposed sale of 429 shares of Madrigal Pharmaceuticals common stock under Rule 144, with an aggregate market value of $215,220.72.

How many Madrigal Pharmaceuticals (MDGL) shares are planned to be sold and at what value?

The notice covers a proposed sale of 429 common shares of Madrigal Pharmaceuticals with an aggregate market value of $215,220.72, to be executed through a broker.

When were the MDGL shares being sold under Form 144 acquired and how?

The 429 MDGL common shares were acquired on 01/16/2026 from the issuer as restricted stock units, in a single acquisition transaction.

When is the proposed sale date for the MDGL shares in the Form 144?

The approximate date of sale for the 429 Madrigal Pharmaceuticals shares is listed as 01/20/2026, with trading to occur on the NASDAQ exchange.

Which broker is handling the Form 144 sale for MDGL shares?

The proposed Rule 144 sale of 429 MDGL common shares will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services at its New York office.

How many Madrigal Pharmaceuticals (MDGL) shares were outstanding according to the Form 144?

The Form 144 states that 22,711,420 shares of Madrigal Pharmaceuticals common stock were outstanding as of the reference point in the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002034056
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MADRIGAL PHARMACEUTICALS, INC.
SEC File Number	001-33277
Address of Issuer	Four Tower Bridge West Conshohocken PENNSYLVANIA 19428
Phone	2678242827
Name of Person for Whose Account the Securities are To Be Sold	SHANNON KELLEY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	429	215220.72	22711420	01/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/16/2026	Restricted Stock Units	Issuer			429	01/16/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The reported sales occur automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/07/2024.
Date of Notice	01/20/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/07/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Shannon Kelley
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)